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Summary Eribulin mesylate (Halaven®) is a novel inhibitor
of microtubule dynamics that has demonstrated a survival
benefit in patients with locally recurrent or metastatic breast
cancer who previously received at least two chemotherapeutic
regimens including an anthracycline and a taxane. Although
trastuzumab is indicated for patients with human epidermal
growth factor receptor 2 positive (HER2+) breast cancer, a
phase 1 study to evaluate tolerability/safety of eribulin mesy-
late with trastuzumab has not been conducted. Therefore, a
study of eribulin mesylate in combination with trastuzumab
was conducted to evaluate dose limiting toxicity (DLT), tol-
erability/safety, pharmacokinetics (PK), and efficacy and to
estimate the recommended dose in Japanese patients with
advanced or recurrent HER2+ breast cancer. Eribulin mesylate
(1.4 mg/m2) was administered on days 1 and 8 of every
3 week cycle. Trastuzumab was administered with a 4 mg/kg
loading dose followed by 2 mg/kg weekly doses or with an
8mg/kg loading dose followed by 6mg/kg tri-weekly doses. A
total of 12 patients (six for each regimen) received eribulin
mesylate and trastuzumab. No DLT was observed and the
recommended dose of eribulin mesylate in combination with
trastuzumab was estimated as 1.4 mg/m2. Common adverse
events were neutropenia, leukopenia, anaemia and alopecia.
This combination therapy was well tolerated and the neutro-
penia observed was manageable. No PK drug-drug interaction
between eribulin and trastuzumab was observed. Since a tran-
sient ejection fraction decreased was observed in two patients,
cardiac function should be routinely assessed in patients re-
ceiving the combination therapy of eribulin mesylate with
trastuzumab (ClinicalTrials.gov Identifier: NCT01432886).
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Introduction
Overexpression of human epidermal growth factor receptor
2 (HER2) occurs in approximately 25 to 30 % of breast
cancers and is associated with a poor prognosis [1, 2].
Trastuzumab is a humanized IgG1 kappa monoclonal anti-
body that selectively binds with high affinity to the extra-
cellular domain of the HER2 protein. The studies of week-
ly trastuzumab monotherapy (4 mg/kg loading dose follow-
ed by 2 mg/kg weekly) and combination with paclitaxel
was active, well tolerated and prolonged survival in patients
with HER2+ metastatic breast cancer [3–5]. Also,
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comparison of tri-weekly trastuzumab (8 mg/kg loading
dose followed by 6 mg/kg tri-weekly dose) with weekly
trastuzumab has shown comparable results in both mono-
therapy and combination therapy with paclitaxel [6, 7]. The
combination therapy of a tubulin-targeted drug and
trastuzumab appeared to have a superior antitumor effect
and a well-tolerated safety profile in the treatment of HER2
+ breast cancer [5, 7–9].
Eribulin mesylate, a non-taxane microtubule dynamics in-
hibitor, is a structurally simplified synthetic analog of the
marine natural product halichondrin B. The inhibitory effects
of eribulin on microtubule dynamics lead to G2/M cell-cycle
blocks, disruption of normal mitotic spindle formation, and
prolonged mitotic blockage followed by apoptotic cell death
[10, 11].
A phase 1 study has been completed in Japanese pa-
tients with solid tumors to evaluate the safety and pharma-
cokinetics (PK) of eribulin mesylate administration on days
1 and 8 of a 21-day cycle. Dose-limiting toxicities (DLTs)
were neutropenia/febrile neutropenia, and the recommended
dose of eribulin mesylate was determined as 1.4 mg/m2
[12]. Based on the results of this phase 1 study in Japan, a
phase 2 study was conducted to evaluate the efficacy and
safety of eribulin mesylate in patients with locally advanced
or metastatic breast cancer previously treated with
anthracycline and taxane. Eribulin mesylate demonstrated
antitumor activity with an objective response rate (ORR) of
21.3 % (17/80 patients) and a manageable safety profile
[13]. This study supported the previous phase 2 study of
eribulin mesylate that demonstrated its antitumor activity
and safety profile in extensively pretreated breast cancer
patients [14, 15].
In a randomized phase 3 study of patients with locally
recurrent or metastatic breast cancer who previously re-
ceived at least two chemotherapeutic regimens including
an anthracycline and a taxane, the efficacy and safety of
eribulin mesylate (1.4 mg/m2, days 1 and 8 of a 21-day
cycle) were compared with the treatment of the physician’s
choice (TPC). Overall survival (OS) was statistically sig-
nificantly longer in the eribulin mesylate group than in the
TPC group (median OS: 13.1 months vs. 10.6 months,
hazard ratio [HR]: 0.81, p=0.041). Furthermore, an updated
analysis of OS confirmed the significant increase in OS of
the eribulin mesylate group compared with the TPC group
(median OS: 13.2 months vs. 10.5 months, HR: 0.81, p=
0.014) [16].
Based on these results, the combination therapy of
eribulin mesylate and trastuzumab was also expected to
provide a superior antitumor effect and favorable safety
profile.
Therefore, a phase 1 study of eribulin mesylate in combi-
nation with trastuzumab in Japanese patients with advanced or
recurrent HER2+ breast cancer was carried out.
Materials and methods
Study design and treatment
This was a multi-center, open-label phase 1 study of eribulin
mesylate with trastuzumab combination therapy in Japanese
patients with advanced or recurrent HER2+ breast cancer
(NCT01432886). This study consisted of Part 1 (weekly dose
of trastuzumab) and Part 2 (tri-weekly dose of trastuzumab) to
evaluate DLT, tolerability/safety, efficacy and PK, and to
estimate the recommended dose of eribulin mesylate in this
combination therapy.
Eribulin mesylate was administered by 2- to 5-minute i.v.
injection on days 1 and 8 of a 21-day cycle. The initial dose
of eribulin mesylate was 1.4 mg/m2 (equivalent to 1.23 mg/
m2 eribulin expressed as free base) in combination with
trastuzumab treatment. Eribulin mesylate was administered
on days 1 and 8, if all of the following criteria were met: (1)
neutrophil count ≥1.0×103/μL, (2) platelet count ≥7.5×104/
μL, and (3) non-hematologic toxicity ≤grade 2 (except grade
3 nausea, vomiting, and diarrhea controllable with anti-
emetic or anti-diarrheal medication and abnormal laboratory
parameters not requiring treatment). If the patient did not
meet the criteria, the administration of the next dose was
delayed. If the patient met the criteria within a 1-week delay,
the 2nd administration of the cycle was implemented, and
the next cycle had to be initiated no sooner than 2 weeks
after the 2nd administration. If the patient did not meet the
criteria within a 1-week delay, the 2nd administration was
skipped. Dose reduction of eribulin mesylate could be
exercised at the discretion of the investigator if the 2nd
administration in a cycle was delayed or skipped. If dose
reduction was necessary, the 1.4 mg/m2 dose of eribulin
mesylate was initially reduced to 1.1 mg/m2 and then further
reduced to 0.7 mg/m2.
In Part 1, trastuzumab was administered by i.v. infusion at
4 mg/kg as a loading dose and at 2 mg/kg weekly. In Part 2,
trastuzumab was administered by i.v. infusion at 8 mg/kg as a
loading dose and at 6 mg/kg tri-weekly. The infusion time of
trastuzumab was 90 min or longer at initial administration and
could be shortened to 30 min from the 2nd administration and
later. Trastuzumab was administered immediately after
eribulin mesylate administration when used in the same day.
Concomitant use of other medications or treatments was
allowed. However, other anti-cancer drugs, investigational
drugs and prophylactic administration of granulocyte-colony
stimulating factor (G-CSF) were not permitted during the
study.
DLT was evaluated in the first cycle, and if DLTs were
observed in none or one of the first three patients, an addi-
tional three patients were to be added at the same dose level. If
none or one of a total of six patients experienced a DLT, the
investigated dose level of eribulin mesylate was to be regarded
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as tolerable with the trastuzumab combination. In the event
that two of six patients reported a DLT, the investigators were
to obtain written or verbal advice from an Independent Safety
Committee on whether to investigate a decreased dose level of
eribulin mesylate (1.1 mg/m2) as the initial dose. The initial
eribulin mesylate dose level was planned to decrease to
1.1 mg/m2 if a DLT was reported in three or more patients.
Patients were to continue to receive eribulin mesylate until
they no longer received clinical benefit, had progressive dis-
ease (PD), or experienced unacceptable toxicity.
The protocol was approved by the Institutional Review
Board and conducted in accordance with the Declaration of
Helsinki.
Patient eligibility
Key inclusion criteria included: 20–74 years of age; histolog-
ically or cytologically confirmed advanced or recurrent breast
cancer; HER2+ tumor score of 3+ by immunohistochemistry
staining or gene amplification by fluorescence in situ hybrid-
ization (FISH); and any of the following, 1) evidence of
recurrence during adjuvant chemotherapy with trastuzumab
and taxane, 2) evidence of recurrence within 6 months after
adjuvant chemotherapy with trastuzumab and taxane or 3)
prior chemotherapy including trastuzumab and taxane for
advanced or recurrent breast cancer; normal function in major
organs; left ventricular ejection fraction (LVEF) ≥60 % by
multigated acquisition scan or echocardiogram (B or M
mode); and Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1.
Key exclusion criteria included: brain metastasis accompa-
nied by clinical symptoms or requiring treatment; severe
active infection requiring treatment; pleural effusions, ascites
or pericardial effusions requiring drainage; pregnancy or
breastfeeding; and refusal of supportive therapy by blood
transfusion. All patients provided written informed consent
prior to any study procedure.
Assessments
DLTs
The following toxicities were to be regarded as DLTs if they
occurred in the first cycle and their causal relationship with the
study treatment could not be ruled out: grade 4 neutropenia
persistent for more than 7 days; grade 3 or above febrile
neutropenia; grade 4 thrombocytopenia or grade 3 thrombo-
cytopenia requiring blood transfusion; and non-hematologic
toxicity ≥grade 3 (unless grade 3 nausea, vomiting and diar-
rhea was controllable with an anti-emetic and anti-diarrheal
medication, or clinical laboratory abnormalities did not re-
quire treatment). It would also be regarded as a DLT if the
2nd eribulin mesylate administration per cycle was delayed
and the study treatment could not be resumed from day 22 of
cycle 1.
Safety
The demographic and disease characteristics of breast cancer
were recorded at baseline and included HER2 status, estro-
gen receptor status, progesterone receptor status, and prior
therapy complications. Safety assessments were made
throughout the study. The factors that were assessed include
adverse events (AEs), vital signs, bodyweight, 12-lead elec-
trocardiogram, multigated acquisition scan or echocardio-
gram, concomitant medications, and clinical laboratory
values (hematology, blood biochemistry and urinalysis).
AEs were assessed on days 1, 8 and 15 of each cycle. AE
severity was classified according to the Japanese version of
Common Terminology Criteria for Adverse Events v4.0. QT
interval corrected for heart rate using Fridericia’s formula
(QTcF) and LVEF assessment were conducted before the
treatment, on day 15 of cycle 1, on day 1 of every 4th cycle,
and if clinically indicated.
PK and biochemical methodology
Blood samples were taken for eribulin PK analysis on days
1 and 8 of the first treatment cycle, pre-dose, end of infu-
sion, 30 min, and 1, 2, 4, 24, 72 and 168 h after drug
administration. Plasma concentrations of eribulin, measured
as the free-base (i.e. non-mesylate) equivalent, were deter-
mined by using the validated liquid chromatography- tan-
dem mass spectrometry method. The lower limit of quanti-
tation was 0.2 ng/mL.
In Part 1, blood samples were taken for trastuzumab PK
analysis on day 1 (pre-dose, end of infusion, and 3, 4, 24 and
72 h after drug administration) and day 8 and 15 (pre-dose) of
cycle 1, and on day 1 (pre-dose) of cycle 2 and later. In Part 2,
blood samples of day 1 (pre-dose and 3, 4, 24, 72, 168 and
336 h after drug administration) of cycle 1 and day 1 (pre-
dose) of cycle 2 and later cycles were taken. Serum concen-
trations of trastuzumab were determined by using the validat-
ed enzyme-linked immunosorbent assay method. The lower
limit of quantitation was 10 μg/mL.
PK parameters for eribulin and trastuzumab were calculat-
ed by a non-compartmental approach by using WinNonlin
software version 6.2 (Pharsight Corporation, CA, USA). The
calculated parameters included: area under the curve extrapo-
lated to infinity (AUC(0-inf)), terminal half-life (t1/2), total
clearance (CL) and volume of distribution at steady state
(Vss). The maximum observed plasma concentration (Cmax)
and time to Cmax (tmax) were directly derived from the data.
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Tumor assessment
Tumor response was assessed by the investigators according
to the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 [17]. Tumor assessments were per-
formed within 28 days prior to the start of treatment, 6 weeks
after the first dose and every 6 weeks thereafter, or sooner, if
there was clinical suspicion of disease progression.
Results
Results are based on data collected until an August 2, 2013,
cutoff date.
Patient characteristics
A total of 12 patients received eribulin mesylate and
trastuzumab, 6 in Part 1 and 6 in Part 2. These patients were
extensively pretreated with a median of 4.5 (range, 1–14) prior
chemotherapy regimens. Patient demographics and baseline
characteristics are shown in Table 1.
Treatment
For the overall population, eribulin mesylate and trastuzumab
were administered for a median of 7 (range, 2–23) cycles, with
eight patients receiving five or more cycles. The numbers of
treatment cycles by patients are shown in Table 2. Treatment
was discontinued in seven patients (58.3 %) due to PD, and
two patients (16.7 %) withdrew due to AEs. Three patients
(25.0 %) continued to receive the study drug treatment at the
time of the cutoff date. Dose adjustment (reduction, delay or
skip) of eribulin mesylate occurred in ten patients (83.3 %);
eight patients (66.7 %) had dose reduction, eight patients
(66.7 %) had dose delay, and five patients (41.7 %) had to
skip one dose per cycle.
DLTs
DLTs were evaluated on the first cycle, and none of the 12
patients experienced DLT. In cycle 1, grade 3 or 4 neutropenia
that led to a dose delay of the day 8 administration of eribulin
mesylate occurred in two patients (16.7 %), and a dose was
skipped in two patients (16.7 %). Two patients (16.7 %)
Table 1 Patient demographics
and baseline characteristics
ECOG Eastern Cooperative On-
cology Group, ER estrogen re-
ceptor, PR progesterone receptor
a Including the number of neoad-
juvant, adjuvant and therapeutic
therapy
Parameter Part 1 (N=6) Part 2 (N=6) Total (N=12)
Age, median (range), years 64.5 (58–72) 47.0 (39–64) 60.0 (39–72)
Race, n (%)
Japanese 6 6 12 (100.0)
ECOG performance status, n (%)
0 3 2 5 (41.7)
1 3 4 7 (58.3)
ER + and/or PR + disease, n (%) 2 3 5 (41.7)
Number of prior anti-cancer drug treatment, n (%)a
1 0 1 1 (8.3)
2 0 1 1 (8.3)
3 2 0 2 (16.7)
4 1 1 2 (16.7)
≥5 3 3 6 (50.0)
Median (range) 5.0 (3–14) 4.5 (1–6) 4.5 (1–14)
Prior trastuzumab treatment, n (%) 6 6 12 (100.0)
Number of prior trastuzumab treatment, n (%)a
1 2 1 3 (25.0)
2 1 3 4 (33.3)
≥3 3 2 5 (41.7)
Median (range) 2.5 (1–5) 2.0 (1–4) 2.0 (1–5)
Prior taxane treatment, n (%) 6 6 12 (100.0)
Number of prior taxane treatment, n (%)a
1 3 4 7 (58.3)
2 2 2 4 (33.3)
3 1 0 1 (8.3)
Prior anthracycline treatment, n (%) 3 3 6 (50.0)
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received concomitant treatment with G-CSF for grade 4 neu-
tropenia. The median time from day 1 of cycle 1 to the
nadir in neutrophil count was 15 days (95 % CI:14, 23),
and the median time to recovery from the nadir to ≤grade 2
neutropenia was 8 days (95 % CI: 4, 9). One of six patients
(16.7 %) skipped a dose of trastuzumab due to an ejection
fraction decreased (grade 2) in Part 1 (weekly dose of
trastuzumab).
Adverse events
The AEs (all grades) experienced by ≥10% of patients and the
total grade 3 or 4 AEs are shown in Table 3. The commonAEs
were similar in Part 1 and 2. Frequently observed hematologic
AEs were neutropenia [100% (grade 3/4: 100%)], leukopenia
[100 % (grade 3/4: 83 %)] and anaemia [67 % (grade 3/4:
0 %)]. G-CSF was administered to three patients (25.0 %).
Frequently observed non-hematologic AEs, which were gen-
erallymild andmanageable, included alopecia (67%), pyrexia
(42 %), decreased appetite (42 %) and rash (42 %) (all grade 1
or 2). Peripheral neuropathy occurred in four patients
(33.3 %), including one patient (8.3 %) with grade 3 neurop-
athy. The AEs that led to study discontinuation were periph-
eral neuropathy in one patient (8.3 %) and tumour pain in one
patient (8.3 %). An ejection fraction decreased (grade 2)
occurred in two patients (16.7 %) (both patients on day 15
of cycle 1 with one patient also in cycle 19), but the patients
recovered after 1 week without treatment. The mean LVEF
transition is shown in Fig. 1. The other cardiac disorders were
second degree atrioventricular block (grade 2) in one patient
(8.3 %) and palpitation (grade 1) in two patients (16.7 %); no
treatments were required for these adverse advents. No grade
5 AEs or serious AEs were observed.
PK
Figure 2 shows the mean plasma eribulin concentration time
profile up to 168 h and Table 4 shows the PK parameters of
eribulin after eribulin mesylate (1.4 mg/m2) administration
over 2 to 5 min with trastuzumab on day 1 of cycle 1 in Part
1 and Part 2, as well as previously reported phase 1 study
results of eribulin mesylate monotherapy in Japanese patients
[12].
In Part 1, the mean values for t1/2, CL and Vss after
administration of eribulin mesylate on day 1 (Table 4) and
Day 8 were 38.1±7.80 and 30.3±3.29 h, 2.47±0.774 and
2.44±0.967 L/h/m2, and 101±45.3 and 77.9±37.6 L/ m2,
respectively. In Part 2, the mean values for t1/2, CL and Vss
after administration of eribulin mesylate on day 1 (Table 4)
and Day 8 were 35.0±10.8 and 31.7±8.58 h, 2.12±0.754 and
1.95±0.721 L/h/m2, and 69.8±11.8 and 58.0±6.99 L/m2,
respectively.
After trastuzumab was administered intravenously in com-
bination with eribulin, trastuzumab was eliminated from the
serum biphasically after reaching the Cmax in both Part 1 and
2. In Part 1, the mean values for t1/2, CL and Vss after
administration of trastuzumab (4 mg/kg) on day 1 were 115
±28.0 h, 0.369±0.0297 mL/h/kg and 62.4±17.9 mL/kg, re-
spectively. In Part 2, the mean values of t1/2, CL and Vss after
administration of trastuzumab (8 mg/kg) on day 1 were 173±
26.7 h, 0.271±0.0343mL/h/kg and 62.0±4.04mL/kg, respec-
tively (Table 5).
Antitumor activity
Tumor responses were evaluated by RECIST version 1.1 in all
12 patients. The ORR was 8.3 % (95 % CI: 0.2, 38.5) and
tumor responses consisted of a partial response (PR) in one
patient (8.3 %), stable disease (SD: including non-complete
response (CR)/non-PD) ≥5 weeks) in ten patients (83.3 %)
and PD in one patient (8.3 %). The disease control rate (CR +
PR + SD ≥11 weeks) was 83.3% (95%CI: 51.6, 97.9) and the
clinical benefit rate (CR + PR + SD ≥23 weeks) was 50.0 %
(95 % CI: 21.1, 78.9) (Table 6).
Discussion
This phase 1 study established the recommended dose of
eribulin mesylate as 1.4 mg/m2 when administered on days
1 and 8 of a 21-day cycle with appropriate dose adjustment in
combination with either weekly trastuzumab (4mg/kg loading
dose, 2 mg/kg/weekly) or tri-weekly trastuzumab (8 mg/kg
loading dose, 6 mg/kg/tri-weekly) in Japanese patients with
advanced or recurrent HER2+ breast cancer. Eribulin mesylate
was suggested to be safe and tolerable in combination with
trastuzumab with the same recommended dose as monother-
apy [12].
There were no DLTs, grade 5 AEs or serious AEs in this
study. The most common AEs of grade 3 or 4 reported in this
study were neutropenia and leukopenia, which were
Table 2 Numbers of treatment cycles by patients
Number of cycles
received, n (%)
Part 1 (N=6) Part 2 (N=6) Total (N=12)
1–2 – 1 1 (8.3)
3–4 2 1 3 (25.0)
5–8 – 3a 3 (25.0)a
9–12 2 – 2 (16.7)
13–16 – 1a 1 (8.3)a
17–20 – – –
≥21 2a – 2 (16.7)a
a 3 patients in total were on treatment as of 2 August 2013
Invest New Drugs (2015) 33:119–127 123
hematologic toxicities also found in prior clinical studies of
eribulin mesylate monotherapy in Japanese patients [12, 13].
All 12 patients experienced neutropenia, but all events were
reversible and easilymanaged with appropriate dose reduction
or a skipped dose. The median time of 8 days required for
resolution from nadir in neutrophil count to ≤grade 2 neutro-
penia in cycle 1 and the low requirement for G-CSF use
(25 %) supported the safety of the defined eribulin mesylate
Table 3 Adverse events (All grades in ≥10 % of patients and grades 3/4 in total)
Part 1 Part 2 Total
All grades Grade 3/4 AEs All grades Grade 3/4 AEs All grades Grade 3/4 AEs
AE preferred term N=6 N=6 N=6 N=6 N=12 N=12
Blood and lymphatic system disorders
Neutropenia 6 6 6 6 12 (100.0) 12 (100.0)
Leukopenia 6 4 6 6 12 (100.0) 10 (83.3)
Anaemia 4 0 4 0 8 (66.7) 0
Lymphopenia 0 0 3 3 3 (25.0) 3 (25.0)
Febrile neutropenia 0 0 1 1 1 (8.3) 1 (8.3)
Cardiac disorders
Palpitations 2 0 0 0 2 (16.7) 0
Gastrointestinal disorders
Nausea 1 0 2 0 3 (25.0) 0
Vomiting 0 0 3 0 3 (25.0) 0
Constipation 2 0 0 0 2 (16.7) 0
Stomatitis 1 0 1 0 2 (16.7) 0
General disorders and administration site conditions
Pyrexia 2 0 3 0 5 (41.7) 0
Malaise 3 0 0 0 3 (25.0) 0
Chest discomfort 1 0 1 0 2 (16.7) 0
Injection site reaction 2 0 0 0 2 (16.7) 0
Infections and infestations
Lung infection 0 0 2 0 2 (16.7) 0
Tonsillitis 1 0 1 0 2 (16.7) 0
Investigations
Alanine aminotransferase increased 2 0 1 0 3 (25.0) 0
Aspartate aminotransferase increased 2 0 1 0 3 (25.0) 0
Blood creatine phosphokinase increased 3 0 0 0 3 (25.0) 0
Ejection fraction decreased 1 0 1 0 2 (16.7) 0
Metabolism and nutrition disorders
Decreased appetite 4 0 1 0 5 (41.7) 0
Hypertriglyceridaemia 1 1 2 2 3 (25.0) 3 (25.0)
Hypophosphataemia 0 0 1 1 1 (8.3) 1 (8.3)
Musculoskeletal and connective tissue disorders
Myalgia 4 0 0 0 4 (33.3) 0
Muscle spasms 2 0 0 0 2 (16.7) 0
Nervous system disorders
Dysgeusia 2 0 2 0 4 (33.3) 0
aPeripheral neuropathy 4 1 0 0 4 (33.3) 1 (8.3)
Headache 0 0 2 0 2 (16.7) 0
Skin and subcutaneous tissue disorders
Alopecia 5 – 3 – 8 (66.7) –
Rash 4 0 1 0 5 (41.7) 0
a Peripheral neuropathy includes neuropathy peripheral and peripheral sensory neuropathy in preferred terms
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administration procedure. The non-hematologic AEs were
consistent with the known safety profile of eribulin, with only
one grade 3 or higher AE with clinical symptoms (grade 3
peripheral neuropathy). The low incidence of neuropathy was
consistent with previous eribulin mesylate studies and the
incidence was also lower when compared with taxane studies
[12–16, 18].
A retrospective review of seven phase 2 and phase 3
trastuzumab clinical trials reported that the patients treatedwith
trastuzumab were at an increased risk of cardiac dysfunction.
The incidence of cardiac dysfunction was highest in patients
receiving concomitant trastuzumab and anthracycline/
cyclophosphamide (27 %). The risk was substantially lower
in patients receiving paclitaxel and trastuzumab (13 %),
t r a s tuzumab a lone (3 to 7 %) , an th racyc l ine /
cyclophosphamide alone (8 %), or paclitaxel alone (1 %)
[19]. To evaluate the risk of cardiac dysfunction in patients
receiving the combination therapy of eribulin mesylate and
trastuzumab, periodic assessments of QTcF and LVEF were
conducted. Although an ejection fraction decreased (grade 2)
was observed in two patients (16.7%), these patients recovered
after 1 week without treatment. Themean LVEF transition was
≥55 % in either part 1 or 2 of the study (Fig. 1). The other
cardiac disorders experienced by patients were second-degree
atrioventricular block and palpitation, which did not require
treatment. Therefore, a clear increased risk of severe cardiac
dysfunction resulting from the addition of eribulin mesylate to
trastuzumab was not suggested from this study. Since a few
cardiac events were observed, cardiac function should be
routinely assessed in patients receiving eribulin mesylate in
combination with trastuzumab, which is consistent with the
recommendation for patients receiving trastuzumab in other
combination therapies. The neutropenia observed was man-
ageable, and the non-hematologic AEs were generally mild.
Thus, treatment with eribulin mesylate (1.4 mg/m2) on days 1
and 8 of a 21-day cycle with appropriate dose adjustment was
regarded as tolerable in combination with trastuzumab (either
weekly or tri-weekly) in Japanese patients.
Analysis Visit
Part 1 (with  weekly trastuzumab)
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Fig. 1 Mean LVEF transition assessed by echocardiogram: Assessment
by B mode echocardiogram at the indicated times. Baseline LVEF was



























Part 1 Day 1 (with weekly trastuzumab)
Part 2 Day 1 (with tri-weekly trastuzumab)
Eribulin monotherapy
0 24 48 72 96 120 144 168 192
Fig. 2 PK analysis of the relationship between mean plasma eribulin
concentration versus time profiles for Parts 1 and 2 of the study and for a
previous phase 1 study [12] (cycle 1, day 1)
Table 4 Pharmacokinetic parameters of eribulin (cycle 1, day 1)
PK Parameter (unit) Part 1 (n=6) Part 2 (n=6) Monotherapy (n=6)
Cmax (ng/mL) 547±128 582±61.0 519.4±107.2
AUC(0-inf) (ng⋅h/mL) 524±137 631±271 672.7±113.7
t1/2 (h) 38.1±7.80 35.0±10.8 39.4±8.3
CL (L/h/m2) 2.47±0.774 2.12±0.754 1.89±0.33
Vss (L/m
2) 101±45.3 69.8±11.8 76.3±19.2
Mean±SD
AUC(0-inf) area under the concentration-time curve from time zero to
infinity, CL total clearance, Cmax maximum plasma concentration, t½
terminal half-life, Vss steady-state volume of distribution
Table 5 Pharmacokinetic parameters of trastuzumab (cycle 1, day 1)
PK parameter (unit) Part 1 (4 mg/kg) (n=6) Part 2 (8 mg/kg) (n=6)
Cmax (μg/mL) 74.9±25.9 194±33.1
AUC (μg⋅h/mL) 10900±868 29800±3740
t1/2 (h) 115±28.0 173±26.7
CL (mL/h/kg) 0.369±0.0297 0.271±0.0343
Vss (mL/kg) 62.4±17.9 62.0±4.04
Mean±SD
AUC(0-inf) area under the concentration-time curve from time zero to
infinity, CL total clearance, Cmax maximum plasma concentration, t½
terminal half-life, Vss steady-state volume of distribution
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The PK profile of eribulin in combination with trastuzumab
was similar between the present study and the previously
reported phase 1 study of eribulin mesylate monotherapy in
Japanese patients [12], including the mean t1/2, volume of
distribution, and renal and systemic clearance (Fig. 2, Table 4),
and as in those studies, the parameters were consistent be-
tween days 1 and 8 of the first cycle. The PK profile of
trastuzumab (Table 5) was also similar to that in the previous
reported phase 1 study of trastuzumab [20]. Combination
therapy of trastuzumab with eribulin mesylate did not appear
to change the PK profile of either eribulin or trastuzumab.
Therefore, no pharmacokinetic drug-drug interaction between
eribulin and trastuzumab was indicated.
Although efficacy was not a primary objective, 8 of 12
patients completed more than 5 cycles of treatment and the
clinical benefit rate (CBR) was 50.0 % (95 % CI: 21.1, 78.9),
which also supports the long-term efficacy and safety of this
combination therapy. Recently, the final results of a phase 2
study of eribulin mesylate (1.4 mg/m2) in combination with
trastuzumab (8mg/kg as a loading dose followed by a 6mg/kg
tri-weekly dose) as a first-line therapy for locally recurrent or
metastatic HER2+ breast cancer was reported. Those results
showed: ORR of 71.2 % (37/52 patients), CBR of 84.6 %
(95 % CI: 71.9, 93.1), median progression free survival of
11.6 months (95 % CI: 9.1, 13.9) and an acceptable safety
profile. The most common AEs of grade 3 or 4 were neutro-
penia (38.5 %) with clinical laboratory hematologic abnor-
malities of neutrophils (55.8 %) and peripheral neuropathy
(26.9 %) [21]. The low incidence of severe neutropenia com-
pared with that of the present study (100%) was considered to
be due to the difference of prior chemotherapy regimen num-
bers. The high incidence of severe peripheral neuropathy
compared with that of the present study (8.3 %) was likely
due to the prolonged duration of treatment in a first-line
setting.
In conclusion, 1.4 mg/m2 eribulin mesylate administered
on days 1 and 8 of a 21-day cycle in combination with either
weekly or tri-weekly trastuzumab was well tolerated in exten-
sively pre-treated Japanese patients with advanced or recur-
rent HER2+ breast cancer. The safety profile shown in the
present study and the reported phase 2 study [21] indicates
that further evaluation of eribulin mesylate and trastuzumab
combination therapy is warranted.
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